Drug Use Investigation for LAMICTAL
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy
Intervention: Lamotrigine (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The purpose of this study is to grasp actual status of usage of lamotrigine tablet and to
collect information for using lamotrigine tablet effectively and safely as well as to grasp
onset status of adverse events in pediatric subjects, geriatric subjects, pregnant women,
subjects with poor renal and hepatic functions.
Clinical Details
Official title: Drug Use Investigation for LAMICTAL
Study design: Time Perspective: Prospective
Primary outcome: The number of adverse events in Japanese subjects with epilepsy treated with lamotrigine tablet
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects with epilepsy having the following seizure types.
- Partial seizures (including secondary generalized seizures)
- Tonic-clonic seizures
- Generalized seizures of Lennox-Gastaut syndrome
Exclusion Criteria:
- None
Locations and Contacts
Additional Information
Related publications: Sunao Kaneko, Yushi Inoue, Masafumi Iijima, Atsuko Ishida, Shogo Inoshiri. Drug Use Investigation of Lamotrigine Tablets in Patients with Epilepsy - Results of Interim Analysis -. 2011;60(3):9-35.
Starting date: December 2008
Last updated: April 16, 2015
|
